SCHEMBL953668

SCHEMBL953668

Cc1nn2ccsc2c1-c1nc(-c2ccc(F)c(F)c2)c(C(=O)O)s1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.38
KDM4E B2RXH2 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.36
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
ADORA1 P30542 1/20 0.33
XDH P47989 3/20 0.33
ALDH1A1 P00352 1/20 0.33
PTGDR2 Q9Y5Y4 2/20 0.32
LDHA P00338 2/20 0.32
KMO O15229 1/20 0.32
DHODH Q02127 1/20 0.32
LDHB P07195 1/20 0.31
MAPT P10636 1/20 0.31
GRM5 P41594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953903 0.91 PTGS2 (0.37) PTGS2CDC7DBF4MAPT
SCHEMBL954223 0.86 CDC7 (0.48) KDM4ERAB9ASMN1; SMN2NPC1POLB
SCHEMBL956983 0.85 CDC7 (0.40) RAB9ASMN1; SMN2NPC1CDC7DBF4
SCHEMBL955757 0.79 SMN1; SMN2 (0.41) KDM4ERAB9ASMN1; SMN2NPC1CDC7
SCHEMBL952078 0.78 CDC7 (0.50) KDM4ERAB9ASMN1; SMN2NPC1GAA
SCHEMBL954281 0.77 PTGS2 (0.32) PTGS2
SCHEMBL6842743 0.77 PTGS2 (0.32) PTGS2
SCHEMBL958333 0.74 CDC7 (0.57) KDM4ECDC7DBF4ALDH1A1DHODH
SCHEMBL954414 0.73 CDC7 (0.37) KDM4ERAB9ASMN1; SMN2NPC1GAA
SCHEMBL954631 0.73 TRPM8 (0.40) RAB9ASMN1; SMN2NPC1CDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 PTGS2 2116/4885KDM4E 1981/4885RAB9A 1059/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 PTGS2 310/4885KDM4E 2304/4885RAB9A 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.